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(n = 1918; mean age 12.1 years; 51.2% male) and adults com-
prised 59.6% (n = 2833; mean age 39.2 years; 23.5% male).
Only 69.3% children and 58.6% adults were in the adherent
group (group 1). Compared with appropriate AI use, AI overuse
was signiﬁcantly associated with increased costs for both chil-
dren ($3541 v. $7670; mean increase 117% [p = 0.001]) and
adults ($3541 v. $5352; mean increase 21% [p = 0.009]). Simi-
larly, compared with appropriate AI use, no AI use with ICS
prescription was signiﬁcantly associated with an increase in costs
for both children and adults (mean increase 51.1% [p = 0.001]
and 37.9% [p = 0.001], respectively). CONCLUSION: Lack of
adherence with evidence-based treatment guidelines remains a
signiﬁcant problem. Interventions to improve guideline adher-
ence have the potential to reduce costs.
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OBJECTIVE: Clinical trials show the efﬁcacy of combination
beta-blocker (BB) and angiotensin converting enzyme inhibitor
(ACEI) or angiotensin II receptor blocker (ARB) therapy for
the treatment of chronic heart failure (CHF). We sought to test
the effectiveness of these drugs in day-to-day health care.
METHODS: The study was a retrospective analysis of a national
cohort of patients diagnosed with CHF from October 1, 1996
through September 30, 2002 identiﬁed from the Department of
Veterans Affairs electronic medical records system. Prevalent
cases with CHF for at least 90 days as of October 1, 2001 (index
date) were analyzed separately from incident cases identiﬁed
after index date. Patients were classiﬁed into four treatment
categories: BB, ACEI or ARB, Both and Neither according to
their exposure after index date. Multiple logistic regression
analysis was employed to assess the adjusted association between
these treatments and mortality within 1 year after index date,
controlling for demographic factors, years with CHF, 30
co-morbidities and co-medications. RESULTS: Prevalent cases:
231,109 patients were identiﬁed, with the crude death rate 8.8%.
Majority of the cohort was male (98.2%) and age >65 years
(76.1%). 28.3% of patients were on beta blockers only, 12.7%
on ACEI or ARB only, 40.1% on both and 18.9% on neither. All
three treatment options showed protective effect as compared to
Neither. Adjusted OR (95% CI) were: BB 0.646 (0.616, 0.677),
ACEI or ARB 0.708 (0.669, 0.749) and Both 0.460 (0.435,
0.488). The same pattern of protective effect remained for inci-
dent cases (N = 68,353). Adjusted OR (95% CI) were: BB 0.713
(0.652, 0.781), ACEI or ARB 0.780 (0.701, 0.868) and Both
0.614 (0.553, 0.681). CONCLUSION: Effectiveness of combi-
nation therapy of beta blockers and angiotensin inhibition was
conﬁrmed, supporting the use of evidence-based care to improve
outcomes in the “real-world” setting.
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OBJECTIVE: To estimate the lifetime cost-effectiveness of can-
desartan (Atacand) in addition to standard care in patients with
HF based on the Low-LVEF trials in the CHARM programme.
METHODS: A stochastic Markov model was developed to esti-
mate resource utilisation, morbidity and mortality effects during
and after the end of the Low-LVEF trials. Trial data were inte-
grated with external data—speciﬁc for Swedish patients—on
morbidity, mortality, and HRQoL. A Weibull hazard function
was estimated on the pooled data from the CHARM-
Alternative and the CHARM-Added trials (Low-LVEF) to
capture the treatment effect of candesartan during 40 months of
follow up. Active treatment is modeled to continue until death,
with identical mortality rates in both arms after end of follow-
up. Age speciﬁc mortality rates were supplied by the Swedish
HF registry. Medical resource were recorded in the CHARM
trials and priced according to public Swedish DRG-tariffs. TTO
based QALY weight estimates for NYHA-classes derive from a
study of 323 Swedish HF patients. Beneﬁts and costs were dis-
counted at 3%. RESULTS: The expected lifetime per patient
direct medical costs and QALYs for candesartan and placebo
were SEK371,000 and SEK 352,000 (1 USD = SEK6.40) and
5.84 and 5.43 QALYs (8.75LY vs 8.17LY) respectively. This
corresponds to an ICER per QALY gained of approximately
SEK46,000 (SEK33,000 per LYG). The CEAC shows that the
likelihood of candesartan representing the cost effective treat-
ment strategy is 0.633, 0.969 and 1 at a willingness-to-pay at
SEK50,000, 60,000, and 70,000 respectively. CONCLUSION:
Candesartan reduces cardiovascular death, hospital admissions,
and all-cause mortality in patients with HF and LVEF  40%
when added to standard therapies. The present study suggests
that long-term treatment with candesartan is highly cost-
effective, both as an alternative to and in addition to ACE-
inhibition, in HF.
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OBJECTIVE: To present immediate and long-term data on the
clinical and economic outcomes associated with major bleeding
during coronary artery bypass graft (CABG) surgery requiring
cardiopulmonary bypass (CPB). METHODS: Using data from
the United States Medicare Public Use Files, we examined clinical
and economic outcomes for patients 65 who underwent an
incident CABG requiring CPB in 2003. Patients were stratiﬁed as
to bleeding status with “Major bleeding” deﬁned as 4 units of
blood transfused. We followed patients for up to two years after
surgery, and compared discharge status, immediate and long-
term morbidity and mortality, and immediate and long-term
costs between those experiencing major bleeding and those not.
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